Yingjie Lu and Richard Malley of Children's Hospital Boston in the U.S. will develop a bivalent pneumococcal and typhoid vaccine by using a new technology to include three highly conserved pneumococcal antigens and the well-established Vi polysaccharide antigen that provides protection against typhoid fever. The team will test the ability of this vaccine to induce strong humoral and cellular immune responses against both pneumococcus and the causative agent of typhoid fever, Salmonella Typhi. In this project's Phase I research, the team successfully developed the bivalent vaccine and in initial research was able to demonstrate dual immunity to both pneumococcus and S. Typhi. In Phase II, they will perform further proof-of-concept experiments in animal models that will provide support for the clinical development of this bivalent vaccine candidate.
More information about Create New Vaccines for Diarrhea, HIV, Malaria, Pneumonia, and Tuberculosis (Round 3)